JP2023509698A - Ｓ１ｐ１受容体に関連した状態の処置方法 - Google Patents

Ｓ１ｐ１受容体に関連した状態の処置方法 Download PDF

Info

Publication number
JP2023509698A
JP2023509698A JP2022541198A JP2022541198A JP2023509698A JP 2023509698 A JP2023509698 A JP 2023509698A JP 2022541198 A JP2022541198 A JP 2022541198A JP 2022541198 A JP2022541198 A JP 2022541198A JP 2023509698 A JP2023509698 A JP 2023509698A
Authority
JP
Japan
Prior art keywords
compound
individual
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509698A5 (enExample
Inventor
エム．クロスビー カトリーヌ
アルワリア ガープリート
クリストファー ウェズレー セルフリッジ アンドリュー
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023509698A publication Critical patent/JP2023509698A/ja
Publication of JP2023509698A5 publication Critical patent/JP2023509698A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022541198A 2020-01-06 2021-01-06 Ｓ１ｐ１受容体に関連した状態の処置方法 Pending JP2023509698A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
US62/957,535 2020-01-06
PCT/US2021/012367 WO2021142030A1 (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Publications (2)

Publication Number Publication Date
JP2023509698A true JP2023509698A (ja) 2023-03-09
JP2023509698A5 JP2023509698A5 (enExample) 2023-12-26

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541198A Pending JP2023509698A (ja) 2020-01-06 2021-01-06 Ｓ１ｐ１受容体に関連した状態の処置方法

Country Status (12)

Country Link
US (1) US20230338336A1 (enExample)
EP (1) EP4087562A4 (enExample)
JP (1) JP2023509698A (enExample)
KR (1) KR20220124209A (enExample)
CN (1) CN115066242A (enExample)
AU (1) AU2021205465A1 (enExample)
BR (1) BR112022012846A2 (enExample)
CA (1) CA3166828A1 (enExample)
IL (1) IL294071A (enExample)
MX (1) MX2022008342A (enExample)
TW (1) TW202135804A (enExample)
WO (1) WO2021142030A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240065283A (ko) * 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
KR102541577B1 (ko) 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) * 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2013510883A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013510884A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的複素環式スフィンゴシン−１−リン酸受容体変調因子
JP2013510885A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469863A2 (en) * 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN110520124A (zh) * 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529049A (ja) * 2008-07-23 2011-12-01 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
JP2013510883A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2013510884A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的複素環式スフィンゴシン−１−リン酸受容体変調因子
JP2013510885A (ja) * 2009-11-13 2013-03-28 レセプトス インコーポレイテッド 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
JP2018504398A (ja) * 2015-01-06 2018-02-15 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
安藤佳洋, 円形脱毛症，[ONLINE], JPN6024048351, 17 May 2017 (2017-05-17), ISSN: 0005603451 *

Also Published As

Publication number Publication date
CN115066242A (zh) 2022-09-16
MX2022008342A (es) 2022-08-04
IL294071A (en) 2022-08-01
TW202135804A (zh) 2021-10-01
KR20220124209A (ko) 2022-09-13
EP4087562A4 (en) 2024-01-10
CA3166828A1 (en) 2021-07-15
US20230338336A1 (en) 2023-10-26
WO2021142030A1 (en) 2021-07-15
BR112022012846A2 (pt) 2022-09-06
EP4087562A1 (en) 2022-11-16
AU2021205465A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
Vossen et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial
EP3661514B1 (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
TWI794885B (zh) 全身紅斑性狼瘡之治療
KR20220124209A (ko) S1p1 수용체와 관련된 이상의 치료 방법
RU2746601C2 (ru) Орвепитант для лечения хронического кашля
AU2024204716A1 (en) Treatment of alopecia areata
KR101802011B1 (ko) 원반성 루푸스에 사용하기 위한 2,4 치환 피리미딘디아민
JP2021510159A (ja) セルドゥラチニブ含有局所皮膚医薬組成物およびその使用
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
Yue et al. Treatment of refractory progressive vitiligo with oral upadacitinib and narrow‐band ultraviolet‐B: A case series.
JP2025514747A (ja) 前頭部線維性脱毛症の治療
Martin et al. Randomized controlled trial of the topical JAK inhibitor delgocitinib cream in patients with frontal fibrosing alopecia
WO2001000196A2 (en) Mirtazapine for weight gain in wasting diseases
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
Khan et al. AB1152 Musculoskeletal manifestation of diabetes mellitus is highly prevalent and is associated with poor diabetic control
JP2024537906A (ja) 粘膜炎を処置するための組成物及び方法
JP5678566B2 (ja) 乾癬予防治療剤
Guerrero et al. AB1151 Polymyalgia rheumatica. new therapeutic strategy based on low dose of metrotexate plus local infiltration with corticosteroids
EP4704843A1 (en) Dosage regimen of orismilast
HK1257770B (en) Treatment of alopecia areata
HK40026724B (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40026724A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527